Juvenile Systemic Sclerosis

Definition And Classification

Complex rare connective tissue disorder characterized by skin hardening and tightening. Believed to involve fetomaternal graft-versus-host reactions in pathogenesis. Differs from localized scleroderma by widespread visceral involvement.

Classified into two distinct subtypes:

Diffuse Cutaneous Systemic Sclerosis: Widespread visceral involvement including gastrointestinal tract, heart, lungs, and kidneys. Skin thickness extends proximal to elbows and knees.
Limited Cutaneous Systemic Sclerosis: Skin thickness restricted to distal extremities and face. Previously known as CREST syndrome (calcinosis, Raynaud phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia). Extremely rare in childhood.

Clinical Manifestations

Cutaneous Features

Insidious disease onset.
Initial phase demonstrates edema spreading proximally from dorsum of hands, fingers, and face.
Progression to induration and fibrosis of skin.
Loss of subcutaneous fat, sweat glands, and hair follicles.
Atrophic skin appears shiny and waxy.
Mask-like facies. Microstomia. Thin lips.
Salt-and-pepper appearance. Hyperpigmented postinflammatory changes surrounded by atrophic depigmentation.
Sclerodactyly. Tapered fingers. Acroosteolysis (resorption of distal tufts of phalanges).
Subcutaneous calcifications (calcinosis) over pressure points.
Skin thickness graded using modified Rodnan skin score (maximum value 51).

Vascular Features

Raynaud phenomenon present in 70% of affected children as initial symptom.
Triphasic sequence: Blanching, cyanosis, and erythema induced by cold or stress.
Digital tip ulcers, infarcts, and gangrene result from severe ischemia.

Visceral Organ Involvement

Pulmonary: Interstitial lung disease and pulmonary arterial hypertension. Major cause of morbidity and mortality. Manifests as dyspnea, exercise intolerance, low diffusing capacity.
Gastrointestinal: Esophageal and intestinal dysmotility. Manifests as dysphagia, gastroesophageal reflux, pseudointestinal obstruction, malabsorption, and failure to thrive.
Cardiac: Myocardial fibrosis, arrhythmias, ventricular hypertrophy, heart failure, and pericardial effusion.
Renal: Hypertension and proteinuria indicate renal involvement. Scleroderma renal crisis is extremely rare in pediatric patients.
Musculoskeletal: Soft tissue contractures, arthralgias, arthritis, myositis. Generalized restriction of joint movements.

Diagnostic Criteria

Diagnosis requires at least one major and at least two minor criteria as per PRES/ACR/EULAR provisional criteria.

Criteria Category	Features
Major Criterion (Required)	Proximal skin sclerosis/induration of skin proximal to metacarpophalangeal or metatarsophalangeal joints.
Minor Criteria (Need $\geq$ 2)
Cutaneous	Sclerodactyly.
Peripheral Vascular	Raynaud phenomenon, nailfold capillary abnormalities, digital tip ulcers.
Gastrointestinal	Dysphagia, gastroesophageal reflux.
Cardiac	Arrhythmias, heart failure.
Renal	Renal crisis, new-onset arterial hypertension.
Respiratory	Pulmonary fibrosis, decreased diffusing capacity, pulmonary arterial hypertension.
Neurologic	Neuropathy, carpal tunnel syndrome.
Musculoskeletal	Tendon friction rubs, arthritis, myositis.
Serologic	Antinuclear antibodies, anti-Scl-70, anticentromere, anti-RNA polymerase III, anti-PM/Scl.

Autoantibody Profile

Antinuclear antibody (ANA) positivity seen in approximately 80% of children. Scleroderma-specific autoantibodies aid in predicting organ involvement.

Autoantibody	Clinical Association
Anti-Scl-70 (Topoisomerase I)	Diffuse cutaneous disease. High risk of interstitial lung disease.
Anti-centromere	Limited cutaneous disease. Rare in childhood.
Anti-RNA polymerase III	Associated with scleroderma renal crisis.
Anti-PM/Scl	Overlap syndrome (polymyositis-scleroderma).

Investigations

Nailfold Capillaroscopy: Differentiates secondary Raynaud phenomenon from primary. Findings include capillary dropouts, architectural disorganization, giant dilated capillary loops, and microhemorrhages.
Radiology: High-resolution CT chest detects interstitial lung disease.
Echocardiography: Assesses pulmonary arterial hypertension and myocardial dysfunction.
Gastrointestinal Evaluation: Barium swallow, esophageal manometry.
Severity Scoring: Juvenile Systemic Sclerosis Severity Score (J4S) evaluates 9 parameters (General, vascular, skin, osteoarticular, muscle, gastrointestinal, respiratory, cardiac, renal). Maximum score 40.

Differential Diagnosis

Condition	Distinguishing Features
Juvenile Localized Scleroderma	Confined to cutaneous manifestations (morphea, linear scleroderma). Lacks visceral organ involvement.
Overlap Syndromes	Mixed features of juvenile dermatomyositis, SLE, or arthritis. Presence of anti-U1-RNP.
Chemically Induced Scleroderma	Exposure to polyvinyl chloride, bleomycin, pentazocine.
Pseudosclerodermas	Phenylketonuria, progeria, porphyria cutanea tarda.
Scleredema	Benign, self-limiting. Non-pitting indurated edema over face, neck, shoulders. Spares hands and feet. Often follows streptococcal infection.

Management

Multidisciplinary approach required. Pharmacotherapy is tailored to specific organ involvement.

Organ System	Treatment Modalities
General / Cutaneous	Avoid cold and sun exposure. Physical therapy. Methotrexate, mycophenolate mofetil, low-dose corticosteroids.
Raynaud Phenomenon	Calcium channel blockers (nifedipine, amlodipine). Phosphodiesterase-5 inhibitors (sildenafil). Topical nitrates, prostacyclins. Avoid calcium channel blockers if severe severe gastroesophageal reflux present.
Interstitial Lung Disease	Cyclophosphamide, mycophenolate mofetil, rituximab.
Pulmonary Hypertension	Endothelin receptor antagonists (bosentan), phosphodiesterase-5 inhibitors (sildenafil).
Renal Crisis	ACE inhibitors (captopril, enalapril). Corticosteroids used cautiously due to risk of precipitating renal crisis.
Gastrointestinal	Small frequent meals. Metoclopramide, erythromycin, omeprazole.
Refractory Disease	Biologics (tocilizumab, rituximab). Autologous stem cell transplantation reserved for severe, refractory interstitial lung disease.

Complications And Prognosis

Slowly progressive disease characterized by periods of remission and exacerbation.
Survival rates in children are 89% at 5 years and 80-87% at 10 years.
Major cause of mortality is cardiopulmonary disease, primarily heart failure secondary to myocardial and pulmonary fibrosis.
Morbidity relates to joint contractures, severe digital ischemia/autoamputation, and gastrointestinal failure. Adult-onset disease carries a worse overall prognosis due to higher rates of interstitial lung disease and renal involvement, but childhood-onset disease causes profound long-term physical restriction.